Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Birch Pollen Allergoid Immunotherapy
NCT00263627Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Jun 2005
- Primary completion
- Jun 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of birch pollen allergoid in birch pollen allergy (2 arms), sponsored by Allergopharma. Primary endpoint: Symptom Medication Score. Started Jun 2005; status: completed.
02
Drugs
birch pollen allergoid
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT00263627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263627.